The United Kingdom and the United States have agreed to a landmark trade agreement that will keep zero import taxes on British pharmaceutical exports going into the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to boost funding on drugs through the NHS. This move secures that tariffs on these key exports will stay at zero for a period of three years.
This agreement follows recent statements to significantly raise tariffs on patented drug products, with potential rates discussed as high as 100%.
"This agreement between the UK strengthens the worldwide climate for new treatments and establishes long-overdue equity to transatlantic pharmaceutical trade," an announcement noted.
Trade Significance
Pharmaceuticals constitute one of the UK's biggest goods shipped to the America, which is clearly the primary buyer for major companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period to the end of last September, the UK exported drugs worth billions to the US. This amount accounted for nearly one-fifth of British export trade in that timeframe.
"This agreement protects work, stimulates capital expenditure and paves the way for the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary remarked.
Specific UK Commitments
The deal includes several specific pledges from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new therapies to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a aim to double overall health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to control costs will be capped at 15%. Last year, refunds were more than twenty percent.
Recent Tensions
The deal follows a ongoing tension between the sector and the British authorities over drug pricing and NHS adoption.
This friction were exacerbated by assertions that US customers were charged significantly more for the identical medicines than patients in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been halted or abandoned, while major expansions have been directed toward American operations.
A senior figure publicly accepted that the NHS had to spend more on drugs, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
